Form 4: REGENXBIO Director Receives Equity Compensation

Director Daniel Tasse was granted 9,807 restricted stock units and 46,600 stock options as part of annual equity compensation.

Summary

• Director Daniel Tasse acquired 9,807 restricted stock units (RSUs) on May 29, 2026.
• Director Daniel Tasse was granted 46,600 stock options with an exercise price of $7.01 per share.
• Both the RSU award and the stock options are subject to a one-year vesting period, becoming fully exercisable on May 29, 2027.
• Following these transactions, the director's total beneficial ownership of common stock increased to 28,861 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard retention mechanism for board members via time-based vesting.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Potential for future dilution if additional equity awards are issued to board members or employees.
• Dependence on the director's continuous service for the vesting of the granted equity.

Future Outlook

The equity grants are subject to continuous service requirements, with full vesting scheduled for May 29, 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• Grant sizes are typical for non-executive directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSU and stock options on May 29, 2027.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Trading, Equity Compensation, Director Compensation, Biotech